골수세포 표적 치료 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global myeloid cell targeting therapeutic market looks promising with opportunities in the oncological disorders and rare disorders markets. The global myeloid cell targeting therapeutic market is expected to grow with a CAGR of 33.1% from 2025 to 2031. The major drivers for this market are the increasing healthcare expenditure and the increased investment in R&D.

• Lucintel forecasts that, within the type category, intravenous injection will remain larger segment over the forecast period due to intravenous injection, as it is the most efficient and effective method.
• Within the application category, oncological disorders is expected to witness the higher growth due to the significant demand for myeloid cell-targeted therapies.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Myeloid Cell Targeting Therapeutic Market

As the myeloid cell targeting therapeutic market evolves, several trends are shaping its future, driving innovation, and expanding its applications. These trends are influenced by advancements in molecular biology, increased understanding of immune modulation, and growing demand for targeted therapies, particularly in oncology. Below are five key trends that are transforming the landscape of myeloid cell targeting.

• Immuno-oncology Integration: Myeloid cell targeted therapies are increasingly being integrated into cancer immunotherapy, particularly to address immune evasion mechanisms. Myeloid-derived suppressor cells (MDSCs) play a key role in creating an immunosuppressive tumor microenvironment, which hampers the effectiveness of conventional therapies. Targeting MDSCs and macrophages is becoming a promising strategy to enhance the efficacy of checkpoint inhibitors, CAR-T therapies, and monoclonal antibodies in oncology. This integration has led to accelerated clinical trials and a growing pipeline of immunotherapies aimed at reprogramming myeloid cells to support anti-tumor immunity.
• Personalized Medicine Approach: Personalized medicine is becoming a major trend in the myeloid cell targeting therapeutic market. By leveraging genetic profiling and immune profiling, researchers are able to identify specific subtypes of myeloid cells that influence disease progression, particularly in cancer and autoimmune disorders. Targeting these specific cell populations with tailored therapies is leading to improved clinical outcomes and fewer side effects. This trend is expected to continue as advances in genomics and immunology allow for better patient stratification, optimizing therapeutic efficacy and safety.
• Combination Therapies: The combination of myeloid cell targeted therapies with other treatments such as chemotherapy, radiation therapy, and biologics is becoming a prominent approach. This trend capitalizes on the synergistic effects of combining immune modulation with conventional treatments to overcome resistance mechanisms. For instance, combining macrophage reprogramming agents with checkpoint inhibitors is showing promise in enhancing tumor responsiveness. This strategy aims to tackle the tumor microenvironment's complexity by addressing multiple facets of immune suppression, improving overall treatment efficacy and reducing relapse rates.
• Expansion in Autoimmune Disease Treatment: While cancer has traditionally been the primary focus of myeloid cell targeting therapies, there is an increasing shift toward autoimmune diseases. Myeloid cells, particularly dendritic cells and macrophages, play a crucial role in the development of autoimmune conditions like rheumatoid arthritis and multiple sclerosis. Targeting these cells to restore immune tolerance is gaining traction as a novel therapeutic approach. This trend is expanding the market's scope, with myeloid-targeted drugs being developed for a broader range of inflammatory diseases beyond oncology.
• Regulatory Advancements and Accelerated Approvals: Regulatory bodies in key regions, including the U.S., China, and the EU, are adopting more flexible and expedited approval pathways for myeloid cell targeting therapies. This trend is driven by the growing need for innovative treatments in oncology and chronic diseases. For example, the FDA's Breakthrough Therapy designation and China's conditional approval process are facilitating faster access to these therapeutics. Regulatory support for early-phase clinical trials and approval of novel immunotherapies is accelerating market growth, allowing myeloid-targeted drugs to reach patients more quickly.

These emerging trends in myeloid cell targeting therapeutics are revolutionizing the treatment landscape. By integrating with cancer immunotherapy, adopting personalized approaches, combining with other treatments, expanding into autoimmune diseases, and benefiting from regulatory advancements, the market is poised for significant growth. These trends are not only driving innovation but are also expanding the therapeutic scope, providing new avenues for treating a wide range of diseases.

Recent Developments in the Myeloid Cell Targeting Therapeutic Market

Recent advancements in myeloid cell targeted therapies have brought about notable progress, particularly in immunotherapy. Researchers are exploring new ways to manipulate myeloid cells, including macrophages, dendritic cells, and MDSCs, to treat cancer and autoimmune diseases. These developments represent an exciting shift in therapeutic strategies, with multiple advancements influencing drug discovery, clinical trials, and market growth. The following are key developments in the myeloid-targeting therapeutics market.

• Breakthroughs in MDSC Modulation for Cancer Treatment: Targeting myeloid-derived suppressor cells (MDSCs) has emerged as a breakthrough in cancer immunotherapy. These cells contribute to tumor-induced immunosuppression, preventing effective anti-cancer immune responses. Recent developments have led to the discovery of novel drugs and immune modulators that can reprogram MDSCs, enhancing the body's immune response to tumors. Early-stage clinical trials are showing promising results, especially in combination with immune checkpoint inhibitors, positioning MDSC modulation as a critical component of next-generation cancer therapies.
• Advances in Targeting Macrophage Polarization: Macrophages can have both pro-inflammatory and anti-inflammatory roles, and targeting macrophage polarization has shown therapeutic potential in cancer and chronic inflammatory diseases. Recent studies have focused on reprogramming macrophages from an immunosuppressive M2 phenotype to a tumoricidal M1 phenotype. Researchers are developing small molecules and biologic agents that can shift macrophage polarization, providing a new therapeutic approach. This strategy is advancing in clinical trials, with early results suggesting improvements in tumor regression and immune system activation.
• New Clinical Trials in Autoimmune Diseases: The focus on myeloid cells is expanding beyond oncology into autoimmune diseases. Recent clinical trials have explored therapies that target dendritic cells and macrophages to modulate immune responses and restore tolerance. These therapies aim to treat conditions like rheumatoid arthritis, lupus, and multiple sclerosis, where immune dysregulation plays a key role. Clinical developments in this area are still in early stages, but they hold promise for improving patient outcomes in autoimmune disease management.
• Collaboration Between Biotech Firms and Academia: There has been a surge in collaboration between biotech companies and academic institutions to advance research in myeloid-targeted therapies. These partnerships are essential for translating laboratory discoveries into clinical applications. Notable collaborations have accelerated the development of novel biomarkers for patient selection, improving the efficacy of therapies targeting myeloid cells. These collaborations are paving the way for the next generation of immunotherapies and expanding the therapeutic applications of myeloid-targeted treatments.
• Increased Investment in Immuno-oncology Drugs: Increased investment from both private and public sectors is fueling innovation in the myeloid cell targeting therapeutic market. Immuno-oncology, particularly therapies that target the tumor microenvironment, has become a major focus for biotech companies. Significant funding has been directed toward research on macrophages, dendritic cells, and MDSCs to overcome immune resistance in tumors. This growing investment is accelerating the development and commercialization of new myeloid-targeted therapies, leading to a more competitive and dynamic market.

Recent developments in the myeloid cell targeting therapeutic market are positioning it as a rapidly advancing and highly dynamic field. From breakthroughs in MDSC modulation to new clinical trials for autoimmune diseases, these advancements are reshaping the therapeutic landscape. Increased investments, academic collaborations, and the expansion into autoimmune diseases and cancer are driving the growth of this market, which holds immense potential for revolutionizing the treatment of various diseases.

Strategic Growth Opportunities in the Myeloid Cell Targeting Therapeutic Market

The myeloid cell targeting therapeutic market presents significant growth opportunities across various applications, including oncology, autoimmune diseases, and chronic inflammatory conditions. These opportunities are fueled by advancements in immunology, regulatory changes, and growing investments in biotech. Understanding these growth areas can help companies and stakeholders capitalize on emerging market trends. Below are key applications driving strategic growth in the myeloid-targeted therapeutics space.

• Cancer Immunotherapy: Cancer immunotherapy remains the largest application for myeloid cell targeted therapeutics. Targeting macrophages, MDSCs, and dendritic cells to modify the tumor microenvironment is showing promising potential in clinical trials. Combining myeloid-targeted therapies with existing treatments like checkpoint inhibitors and CAR-T therapies is expected to significantly enhance tumor response rates. This area is likely to see rapid growth as more companies develop drugs to modulate the immune system's ability to recognize and attack cancer cells.
• Autoimmune Disease Treatment: There is a growing recognition of the role myeloid cells play in autoimmune diseases. Targeting dendritic cells and macrophages to restore immune tolerance presents a promising approach for treating conditions like rheumatoid arthritis, lupus, and multiple sclerosis. As the understanding of myeloid cell biology deepens, therapeutic strategies aimed at these cells are becoming a key opportunity for growth. This expanding application in autoimmune diseases is expected to become a significant driver for the market.
• Chronic Inflammatory Disease Management: Chronic inflammatory diseases, such as asthma and inflammatory bowel disease (IBD), present a large unmet medical need. Myeloid cells, especially macrophages, play a central role in chronic inflammation. Targeting these cells to modulate inflammatory responses is a key growth opportunity. Novel myeloid-targeted therapies could offer more effective treatments with fewer side effects compared to traditional anti-inflammatory drugs. This segment is expected to grow as new therapeutics are developed for managing chronic inflammation.
• Rare Disease Treatment: Targeting myeloid cells for rare diseases, such as certain types of genetic immunodeficiency's and lysosomal storage disorders, are an emerging growth area. These conditions often involve immune dysregulation, making myeloid cells an attractive therapeutic target. While the market for rare diseases is smaller, the potential for breakthroughs and orphan drug designations presents strategic opportunities for growth in this niche.
• Next-Generation Therapeutics Development: The development of next-generation myeloid-targeted therapeutics, including gene editing tools like CRISPR and RNA-based therapies, presents a promising growth opportunity. These advanced technologies allow for highly precise targeting of myeloid cells, potentially offering curative treatments for various diseases. This area is still in early development stages but could revolutionize the treatment of myeloid-related disorders in the near future.

Strategic growth opportunities in the myeloid cell targeting therapeutic market are diverse and expanding across multiple applications. Oncology, autoimmune diseases, chronic inflammation, and rare diseases offer significant potential for market players. As research continues to unlock the therapeutic potential of myeloid cell modulation, these opportunities will drive the development of innovative therapies, reshaping the future of immunotherapy.

Myeloid Cell Targeting Therapeutic Market Driver and Challenges

The myeloid cell targeting therapeutic market is shaped by various drivers and challenges, ranging from technological innovations to regulatory hurdles. Understanding these factors is essential for stakeholders aiming to capitalize on the market's growth potential. The following section explores the key drivers and challenges that are influencing the market dynamics.

The factors responsible for driving the myeloid cell targeting therapeutic market include:

1. Technological Advancements in Immunotherapy: Recent technological innovations in immunotherapy, including the development of immune checkpoint inhibitors and CAR-T therapies, are driving the myeloid cell targeting therapeutic market. These advancements enable the targeting of myeloid cells to enhance immune responses against tumors and other diseases. The growing understanding of myeloid cell biology is opening up new therapeutic avenues, accelerating market growth.

2. Increasing Cancer Incidence and Unmet Medical Needs: The rising incidence of cancer globally is a major driver of the myeloid cell targeting therapeutic market. Cancer therapies that can manipulate the tumor microenvironment, including targeting myeloid cells, are in high demand. The limited effectiveness of conventional therapies and the need for more personalized treatments create a significant opportunity for myeloid-targeted therapies.

3. Growing Investment in Biotechnology: Increased investment in biotechnology, particularly in the immunotherapy and cell-based therapy sectors, is fueling the development of myeloid cell targeted therapeutics. With funding from both public and private sectors, research and development in this area are accelerating. These investments are supporting clinical trials, regulatory approvals, and commercialization efforts, further propelling market growth.

4. Favorable Regulatory Environment: The regulatory environment in key regions, including the U.S., China, and the EU, is evolving to support faster approvals for myeloid-targeted therapies. Agencies like the FDA and EMA are facilitating the development of novel immunotherapies through accelerated approval processes. This regulatory support is driving the market by reducing development timelines and improving access to innovative treatments.

5. Advancements in Personalized Medicine: The shift toward personalized medicine is a significant driver in the myeloid cell targeting therapeutic market. By leveraging genomic and immune profiling, companies can develop therapies tailored to individual patients. This trend is improving treatment outcomes and expanding the use of myeloid-targeted therapies in personalized cancer treatment and autoimmune disease management.

Challenges in the myeloid cell targeting therapeutic market are:

1. High Development Costs: The high costs associated with developing myeloid-targeted therapeutics pose a significant challenge. Research and clinical trials for immunotherapies are expensive, and the need for specialized manufacturing processes adds to the cost burden. These financial challenges could limit the accessibility of myeloid-targeted therapies, especially in low-income regions.

2. Regulatory Complexity: Despite regulatory advancements, navigating the complex regulatory pathways for new myeloid-targeted therapies remains challenging. Differences in approval processes across regions can delay market entry and increase development costs. Furthermore, the need for extensive clinical data to demonstrate safety and efficacy adds to the regulatory burden.

3. Limited Understanding of Myeloid Cell Biology: While progress has been made, there is still much to learn about the complex biology of myeloid cells. A deeper understanding is needed to effectively target these cells and predict how therapies will interact with the immune system. The lack of comprehensive knowledge may slow down the development of effective and precise therapies.

The myeloid cell targeting therapeutic market is driven by technological advancements, increasing cancer rates, growing biotechnology investments, and favorable regulatory environments. However, challenges such as high development costs, regulatory complexity, and limited understanding of myeloid cell biology could hinder growth. Addressing these issues will be crucial to fully unlocking the market's potential.

List of Myeloid Cell Targeting Therapeutic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myeloid cell targeting therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myeloid cell targeting therapeutic companies profiled in this report include-

• ChemoCentryx
• Daiichi Sankyo
• Gilead Sciences
• Janssen Biotech
• Roche
• Pfizer
• GlaxoSmithKline
• Macrophage Pharma
• Enlivex
• Immune-Onc Therapeutics

Myeloid Cell Targeting Therapeutic Market by Segment

The study includes a forecast for the global myeloid cell targeting therapeutic market by type, application, and region.

Myeloid Cell Targeting Therapeutic Market by Type [Value from 2019 to 2031]:

• Intravenous Injection
• Oral
• Others

Myeloid Cell Targeting Therapeutic Market by Application [Value from 2019 to 2031]:

• Oncological Disorders
• Rare Disorders
• Others

Myeloid Cell Targeting Therapeutic Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Myeloid Cell Targeting Therapeutic Market

The myeloid cell targeting therapeutic market, focused on targeting immune cells like macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs), is witnessing significant advancements due to breakthroughs in immunotherapy. This sector is gaining attention as researchers explore ways to modulate myeloid cell activity for conditions like cancer, autoimmune diseases, and chronic inflammation. Major developments are underway in the United States, China, Germany, India, and Japan, where innovative therapeutic strategies and regulatory frameworks are accelerating. This progress is shaping the future of immunotherapy, with the potential to revolutionize treatment paradigms in oncology and immunology.

• United States: The U.S. remains a global leader in myeloid cell targeted therapeutics, with substantial investments in research and development. The approval of several immunomodulatory drugs and clinical trials focusing on MDSC modulation are driving the market. Key players are exploring novel approaches like checkpoint inhibitors and CAR-T therapies aimed at enhancing immune system activation. The collaboration between biotechnology companies and academic institutions is fostering innovation, and regulatory agencies like the FDA are facilitating faster approval pathways for myeloid-targeting drugs. These advancements are promising to enhance the treatment landscape for cancer and chronic inflammatory diseases in the U.S.
• China: China has seen rapid advancements in the myeloid cell targeting therapeutic market, with a growing focus on immunotherapy to treat cancer and autoimmune diseases. The Chinese government's support for biopharma R&D, along with favorable regulatory policies, has led to an increase in clinical trials investigating myeloid cell modulation. Notably, research on MDSCs as immune suppressors in tumors is gaining momentum. Chinese biotech companies are collaborating with international firms, boosting innovation and expanding the market for myeloid-targeted therapies. The government's "Made in China 2025" initiative is further accelerating the development of these therapies.
• Germany: Germany is emerging as a key hub for myeloid cell targeted research in Europe, driven by strong public-private collaborations. The country's pharmaceutical sector is heavily investing in understanding how myeloid cells can be reprogrammed to fight cancer. Ongoing clinical trials are exploring therapies targeting macrophages and dendritic cells in various cancers, including breast cancer and glioblastoma. German universities and research institutes are leaders in the development of biomarkers and diagnostic tools to identify patients who could benefit from myeloid-targeted therapies. Regulatory bodies are facilitating faster approvals, contributing to the market's growth in Europe.
• India: India's myeloid cell targeting therapeutic market is in the early stages, but it holds significant potential due to the country's growing biotech ecosystem and large patient population. Research and clinical trials focusing on immunomodulatory drugs are expanding, with particular interest in cancer and autoimmune diseases. Indian pharmaceutical companies are increasingly collaborating with international biotech firms, bringing affordable therapies to the local market. Government support for biopharma innovation is boosting the development of myeloid-targeted therapies. However, market growth faces challenges due to regulatory hurdles and a lack of robust healthcare infrastructure for advanced therapies.
• Japan: Japan is an important player in the myeloid cell targeting therapeutic market, with the government prioritizing biopharma innovation. Japan's Ministry of Health, Labor, and Welfare (MHLW) has been supportive of early-phase clinical trials and regulatory approvals for immunotherapy targeting myeloid cells. Japanese pharmaceutical giants are heavily investing in cancer immunotherapy, particularly in targeting macrophages and MDSCs. The country's aging population and high incidence of cancers are driving demand for novel immunotherapies. Additionally, Japan's collaborative approach between industry and academia accelerates the development of cutting-edge therapeutics, positioning the country as a global leader in this space.

Features of the Global Myeloid Cell Targeting Therapeutic Market

• Market Size Estimates: Myeloid cell targeting therapeutic market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Myeloid cell targeting therapeutic market size by type, application, and region in terms of value ($B).
• Regional Analysis: Myeloid cell targeting therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the myeloid cell targeting therapeutic market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myeloid cell targeting therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the myeloid cell targeting therapeutic market by type (intravenous injection, oral, and others), application (oncological disorders, rare disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Myeloid Cell Targeting Therapeutic Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Intravenous Injection: Trends and Forecast (2019-2031)
• 4.4 Oral: Trends and Forecast (2019-2031)
• 4.5 Others: Trends and Forecast (2019-2031)

5. Global Myeloid Cell Targeting Therapeutic Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Oncological Disorders: Trends and Forecast (2019-2031)
• 5.4 Rare Disorders: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Myeloid Cell Targeting Therapeutic Market by Region

7. North American Myeloid Cell Targeting Therapeutic Market

• 7.1 Overview
• 7.4 United States Myeloid Cell Targeting Therapeutic Market
• 7.5 Mexican Myeloid Cell Targeting Therapeutic Market
• 7.6 Canadian Myeloid Cell Targeting Therapeutic Market

8. European Myeloid Cell Targeting Therapeutic Market

• 8.1 Overview
• 8.4 German Myeloid Cell Targeting Therapeutic Market
• 8.5 French Myeloid Cell Targeting Therapeutic Market
• 8.6 Spanish Myeloid Cell Targeting Therapeutic Market
• 8.7 Italian Myeloid Cell Targeting Therapeutic Market
• 8.8 United Kingdom Myeloid Cell Targeting Therapeutic Market

9. APAC Myeloid Cell Targeting Therapeutic Market

• 9.1 Overview
• 9.4 Japanese Myeloid Cell Targeting Therapeutic Market
• 9.5 Indian Myeloid Cell Targeting Therapeutic Market
• 9.6 Chinese Myeloid Cell Targeting Therapeutic Market
• 9.7 South Korean Myeloid Cell Targeting Therapeutic Market
• 9.8 Indonesian Myeloid Cell Targeting Therapeutic Market

10. ROW Myeloid Cell Targeting Therapeutic Market

• 10.1 Overview
• 10.4 Middle Eastern Myeloid Cell Targeting Therapeutic Market
• 10.5 South American Myeloid Cell Targeting Therapeutic Market
• 10.6 African Myeloid Cell Targeting Therapeutic Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Myeloid Cell Targeting Therapeutic Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 ChemoCentryx
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Daiichi Sankyo
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Gilead Sciences
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Janssen Biotech
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Roche
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Pfizer
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 GlaxoSmithKline
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Macrophage Pharma
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Enlivex
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Immune-Onc Therapeutics
  • Company Overview
  • Myeloid Cell Targeting Therapeutic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us